Understanding high-risk smoldering multiple myeloma

References

• Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302(24):1347–1349.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Kainz S, Schreder M, et al. SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis. EClinicalMedicine. 2023;58:101910.
   PubMedGoogle Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582–2590.
   PubMed Web of Science ®Google Scholar
• Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59.
   PubMedGoogle Scholar
• Cowan A, Ferrari F, Freeman SS, et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 2023;10(3):e203–e212.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Hernández M-T, Salvador C, et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study. Eur J Cancer. 2022;174:243–250.
   PubMed Web of Science ®Google Scholar
• Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38(11):1126–1137.
   PubMed Web of Science ®Google Scholar
• Pérez-Persona E, Vidriales M-B, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586–2592.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Kumar S, Dimopoulos MA, et al. International myeloma working group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102.
   PubMed Web of Science ®Google Scholar
• Visram A, Rajkumar SV, Kapoor P, et al. Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer J. 2021;11(11):186.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Lobato LG, de Daniel I Bisbe A, Tovar N, et al. Evolving pattern improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma. Blood. 2022;140(Suppl 1):4341–4342.
   Google Scholar
• Bustoros M, Anand S, Sklavenitis-Pistofidis R, et al. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun. 2022;13(1):3449.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106(7):2276–2279.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Rajkumar SV, Dispenzieri A, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. 2017;31(1):130–135.
   PubMed Web of Science ®Google Scholar
• Termini R, Žihala D, Terpos E, et al. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clin Cancer Res. 2022;28(21):4771–4781.
   PubMed Web of Science ®Google Scholar
• Kumar S, Rajkumar SV, Greipp PR, et al. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments. Am J Hematol. 2004;77(1):7–11.
   PubMed Web of Science ®Google Scholar
• Aljama MA, Sidiqi MH, Lakshman A, et al. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv. 2018;2(22):3149–3154.
   PubMed Web of Science ®Google Scholar
• Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985–1005.
   PubMed Web of Science ®Google Scholar
• Laurent SA, Hoffmann FS, Kuhn P-H, et al. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6(1):7333.
   PubMedGoogle Scholar
• Visram A, Soof C, Rajkumar S, et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J. 2021;11(6):120.
   PubMed Web of Science ®Google Scholar
• Bolli N, Martinelli G, Cerchione C. The molecular pathogenesis of multiple myeloma. Hematol Rep. 2020;12(3):9054.
   PubMed Web of Science ®Google Scholar
• Wiedmeier-Nutor JE, Bergsagel PL. Review of multiple myeloma genetics including effects on prognosis, response to treatment, and diagnostic workup. Life. 2022;12(6):812.
   PubMedGoogle Scholar
• Bolli N, Maura F, Minvielle S, et al. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018;9(1):1–10.
   PubMedGoogle Scholar
• Merz M, Hielscher T, Schult D, et al. Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma. Leukemia. 2020;34(4):1192–1196.
   PubMed Web of Science ®Google Scholar
• Dosani T, Mailankody S, Korde N, et al. Host-related immunodeficiency in the development of multiple myeloma. Leuk Lymphoma. 2018;59(5):1127–1132.
   PubMed Web of Science ®Google Scholar
• Zavidij O, Haradhvala NJ, Mouhieddine TH, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1(5):493–506.
   PubMedGoogle Scholar
• Botta C, Maia C, Garcés J-J, et al. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. Blood Adv. 2022;6(2):690–703.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(12):1685–1717.
   PubMedGoogle Scholar
• Bergstrom DJ, Kotb R, Louzada ML, et al. Consensus guidelines on the diagnosis of multiple myeloma and related disorders: recommendations of the myeloma Canada research network consensus guideline consortium. Clin Lymphoma Myeloma Leuk. 2020;20(7):e352–e367.
   PubMed Web of Science ®Google Scholar
• Musto P, Engelhardt M, Caers J, et al. 2021 European myeloma network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica. 2021;106(11):2799–2812.
   PubMed Web of Science ®Google Scholar
• Ojo AS, Akinyemi O, Araoye MO, et al. Early intervention with a curative intent through an intensive therapy versus immunologic disease control using a minimal intensity approach in the management of high-risk smoldering multiple myeloma: a systematic review of evidence from clinical trials. Clin Lymphoma Myeloma Leuk. 2023;23(1):e27–e40.
   PubMed Web of Science ®Google Scholar
• Ojo AS, Ojukwu SG, Asemota J, et al. The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials. J Cancer Res Clin Oncol. 2022;148(4):897–911.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–447.
   PubMed Web of Science ®Google Scholar
• Brighton TA, Khot A, Harrison SJ, et al. Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myelomasiltuximab in high-risk smoldering multiple myeloma. Clin Cancer Res. 2019;25(13):3772–3775.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Hill E, Dew A, et al. Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: a phase 2 nonrandomized controlled trial. JAMA Oncol. 2021;7(11):1678–1685.
   PubMed Web of Science ®Google Scholar
• Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1(6):746–754.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Alsina M, Laplant B, et al. Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high risk smoldering multiple Myeloma-Results of the ascent trial. Blood. 2022;140(Suppl 1):1830–1832.
   Google Scholar
• Mateos M-V, Martínez-López J, Rodríguez-Otero P, et al. Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): post-Hoc analysis of sustained undetectable measurable residual disease (MRD). Blood. 2022;140(Suppl 1):292–294.
   Google Scholar
• Mateos M-V, Martinez Lopez J, Rodríguez-Otero P, et al. Curative strategy (GEM-CESAR) for High-Risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with krd and maintenance with Rd. Blood. 2021;138(Suppl 1):1829–1829.
   Google Scholar
• Covut F, Chopra R, Areti SS, et al. Early onset of smoldering disease correlates with rapid progression to symptomatic multiple myeloma. Blood. 2022;140(Suppl 1):10816–10817.
   Google Scholar
• Tan C, Usmani SZ. Daratumumab, lenalidomide, and dexamethasone for High-Risk smoldering multiple myeloma. Hematologist. 2023;20(2). DOI: https://doi.org/10.1182/hem.V20.2.202329, https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V20.2.202329/494479/Daratumumab-Lenalidomide-and-Dexamethasone-for
   Google Scholar